
Opinion|Videos|February 1, 2024
Key Takeaways from 2024 ASCO GI Cancers Symposium
Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5








































